Nefopam Clinical data Trade names néfopam medisol AHFS/ Drugs.com International Drug Names Routes of administration Oral, intramuscular, intravenous ATC code Legal status Legal status
AU: S4 (Prescription only) UK: POM (Prescription only) Pharmacokinetic data Bioavailability Low  Protein binding 70–75% (mean 73%)   Metabolism Liver ( N- demethylation, others)  Metabolites Desmethylnefopam, others  Elimination half-life Nefopam: 3–8 hours  Desmethylnefopam: 10–15 hours  Excretion Urine: 79.3%  Feces: 13.4%  Identifiers
RS)-5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine CAS Number PubChem CID ChemSpider UNII KEGG ChEBI CompTox Dashboard ( EPA) ECHA InfoCard 100.033.757 Chemical and physical data Formula C 17 H 19 N O Molar mass g·mol 253.345 −1 3D model ( JSmol)
(what is this?) (verify) Nefopam, sold under the brand name Acupan among others, is a centrally acting, non- opioid painkilling medication, that is primarily used to treat moderate to severe pain.
Nefopam acts in the brain and spinal cord to relieve pain via novel mechanisms:
antinociceptive effects from triple monoamine reuptake inhibition, and antihyperalgesic activity through modulation of glutamatergic transmission.
Nefopam is effective for prevention of shivering during surgery or recovery from surgery.
 Nefopam was significantly more effective than  aspirin as an analgesic in one clinical trial, although with a greater incidence of side effects such as sweating, dizziness and nausea, especially at higher doses.   The estimated relative potency of nefopam to morphine indicates that 20 mg of nefopam HCl is the approximate analgesic equal of 12 mg of morphine with comparable analgesic efficacy to morphine,    or  oxycodone, while nefopam tends to produce fewer side effects, does not produce respiratory depression,  and has much less  abuse potential, and so is useful either as an alternative to opioid analgesics, or as an adjunctive treatment for use alongside opioids or other types of analgesics.  Nefopam is also used to treat severe  hiccups.
Nefopam is contraindicated in people with convulsive disorders, those that have received treatment with irreversible
monoamine oxidase inhibitors such as phenelzine, tranylcypromine or isocarboxazid within the past 30 days and those with myocardial infarction pain, mostly due to a lack of safety data in these conditions.
Common side effects include nausea, nervousness, dry mouth, light-headedness and
urinary retention. Less common side effects include vomiting, blurred vision, drowsiness, sweating, insomnia, headache, confusion, hallucinations, tachycardia, aggravation of angina and rarely a temporary and benign pink discolouration of the skin or  erythema multiforme.
Overdose and death have been reported with nefopam. Overdose usually manifests with  convulsions, hallucinations, tachycardia, and hyperdynamic circulation. Treatment is usually supportive, managing cardiovascular complications with  beta blockers and limiting absorption with activated charcoal.
It has additive anticholinergic and sympathomimetic effects with other agents with these properties.
Its use should be avoided in people receiving some types of antidepressants (  tricyclic antidepressants or monoamine oxidase inhibitors) as there is the potential for serotonin syndrome or hypertensive crises to result.
mechanism of action of nefopam and its analgesic effects are not well understood, although inhibition of the reuptake of serotonin, norepinephrine, and to a lesser extent dopamine (that is, acting as an ) is thought to be involved. SNDRI  It also reduces  glutamate signaling via modulating sodium and calcium channels. 
absolute bioavailability of nefopam is low. It is reported to achieve therapeutic plasma concentrations between 49 and 183 nM.  The drug is approximately 73%  protein-bound across a plasma range of 7 to 226 ng/mL (28–892 nM). The  metabolism of nefopam is hepatic, by N- demethylation and via other routes. Its  terminal half-life is 3 to 8 hours, while that of its active metabolite, desmethylnefopam, is 10 to 15 hours. It is  eliminated mostly in urine, and to a lesser extent in feces.
Nefopam is a
cyclized analogue of orphenadrine, diphenhydramine, and tofenacin, with each of these compounds different from one another only by the presence of one or two carbons.   The  ring system of nefopam is a benzoxazocine system. 
Society and culture
Recreational use of nefopam has rarely been reported,
and is far less common than with opioid analgesics. 
In the 1960s, when it was first developed, it had the generic name
^ a b c d e f g h i j k l m
Sanga M, Banach J, Ledvina A, Modi NB, Mittur A (November 2016). "Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 46 (11): 1001–16. doi: 10.3109/00498254.2015.1136989. PMID 26796604. S2CID 34603935.
Seyffart G (6 December 2012). . Springer Science & Business Media. pp. 407–. Drug Dosage in Renal Insufficiency ISBN . 978-94-011-3804-8
Brayfield, A, ed. (27 October 2016). "Nefopam hydrochloride". MedicinesComplete. London, UK: Pharmaceutical Press . Retrieved . 4 September 2017
^ a b c
Girard P, Chauvin M, Verleye M (January 2016). "Nefopam analgesia and its role in multimodal analgesia: A review of preclinical and clinical studies". Clinical and Experimental Pharmacology & Physiology. 43 (1): 3–12. doi: . 10.1111/1440-1681.12506 PMID 26475417.
Kang P, Park SK, Yoo S, Hur M, Kim WH, Kim JT, Bahk JH (January 2019). "Comparative effectiveness of pharmacologic interventions to prevent shivering after surgery: a network meta-analysis". Minerva Anestesiologica. 85 (1): 60–70. doi: 10.23736/S0375-9393.18.12813-6. PMID 30226340.
Alfonsi P, Adam F, Passard A, Guignard B, Sessler DI, Chauvin M (January 2004). "Nefopam, a nonsedative benzoxazocine analgesic, selectively reduces the shivering threshold in unanesthetized subjects". Anesthesiology. 100 (1): 37–43. doi: 10.1097/00000542-200401000-00010. PMC . 1283107 PMID 14695722.
Cohen A, Hernandez CM (1976). "Nefopam hydrochloride: new analgesic agent". The Journal of International Medical Research. 4 (2): 138–43. doi: 10.1177/030006057600400211. PMID 799984. S2CID 41618926.
Wang RI, Waite EM (July 1979). "The clinical analgesic efficacy of oral nefopam hydrochloride". Journal of Clinical Pharmacology. 19 (7): 395–402. doi: 10.1002/j.1552-4604.1979.tb02498.x. PMID 479385.
Pillans PI, Woods DJ (September 1995). "Adverse reactions associated with nefopam". The New Zealand Medical Journal. 108 (1008): 382–4. PMID 7566787.
Sunshine A, Laska E (November 1975). "Nefopam and morphine in man". Clinical Pharmacology and Therapeutics. 18 (5 Pt 1): 530–4. doi: 10.1002/cpt1975185part1530. PMID 1102231. S2CID 19051105.
Phillips G, Vickers MD (October 1979). "Nefopam in postoperative pain". British Journal of Anaesthesia. 51 (10): 961–5. doi: 10.1093/bja/51.10.961. PMID 391253.
^ a b
Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (April 1980). "Nefopam: a review of its pharmacological properties and therapeutic efficacy". Drugs. 19 (4): 249–67. doi: 10.2165/00003495-198019040-00001. PMID 6991238. S2CID 24713213.
Tigerstedt I, Tammisto T, Leander P (December 1979). "Comparison of the analgesic dose-effect relationships of nefopam and oxycodone in postoperative pain". Acta Anaesthesiologica Scandinavica. 23 (6): 555–60. doi: 10.1111/j.1399-6576.1979.tb01486.x. PMID 397711. S2CID 40976610.
Gasser JC, Bellville JW (August 1975). "Respiratory effects of nefopam". Clinical Pharmacology and Therapeutics. 18 (2): 175–9. doi: 10.1002/cpt1975182175. PMID 1097153. S2CID 22220503.
Kapfer B, Alfonsi P, Guignard B, Sessler DI, Chauvin M (January 2005). "Nefopam and ketamine comparably enhance postoperative analgesia". Anesthesia and Analgesia. 100 (1): 169–74. doi: 10.1213/01.ANE.0000138037.19757.ED. PMC . 1283103 PMID 15616073.
Bilotta F, Rosa G (December 2000). "Nefopam for severe hiccups". The New England Journal of Medicine. 343 (26): 1973–4. doi: 10.1056/nejm200012283432619. PMID 11186682.
^ a b c d e f g
"Data Sheet ACUPAN™ Nefopam hydrochloride 30 mg tablets 20 mg intramuscular injection" (PDF). Medsafe New Zealand. iNova Pharmaceuticals (New Zealand) Limited. 3 September 2007 . Retrieved . 10 March 2014
^ a b
Bismuth C, Fournier PE, Bavoux E, Husson O, Lafon D (September 1987). "[Chronic abuse of the analgesic nefopam (Acupan)]". Journal de Toxicologie Clinique et Expérimentale (in French). 7 (5): 343–6. PMID 3448182.
Roth, BL; Driscol, J. "PDSP K. i Database" Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . Retrieved . 14 August 2017
^ a b
Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. (July 2012). "Identifying mechanism-of-action targets for drugs and probes" (PDF). Proceedings of the National Academy of Sciences of the United States of America. 109 (28): 11178–83. Bibcode: 2012PNAS..10911178G. doi: 10.1073/pnas.1204524109. PMC . 3396511 PMID 22711801.
Bausch & Lomb (NZ) Ltd (17 May 2017). "NEW ZEALAND DATA SHEET ACUPAN(TM)" (PDF). Medsafe. New Zealand The Ministry of Health . Retrieved . 4 September 2017
^ a b
Kim KH, Abdi S (April 2014). "Rediscovery of nefopam for the treatment of neuropathic pain". The Korean Journal of Pain. 27 (2): 103–11. doi: 10.3344/kjp.2014.27.2.103. PMC . 3990817 PMID 24748937.
^ a b
Wermuth CG, Aldous D, Raboisson P, Rognan D (1 July 2015). . Elsevier Science. pp. 250–251. The Practice of Medicinal Chemistry ISBN . 978-0-12-417213-5
Sneader W (23 June 2005). . John Wiley & Sons. pp. 405–. Drug Discovery: A History ISBN . 978-0-471-89979-2
Kubinyi H, Müller G (6 March 2006). . John Wiley & Sons. pp. 54–. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective ISBN . 978-3-527-60402-9
Cruz A (2014). . CRC Press. pp. 176–. Therapeutic Hypothermia
Tracqui A, Berthelon L, Ludes B (May 2002). "Fatal overdosage with nefopam (Acupan)" (PDF). Journal of Analytical Toxicology. 26 (4): 239–43. doi: 10.1093/jat/26.4.239. PMID 12054367.